Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Growing patent filings and tier-2 innovators reflect expanding national research base
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Subscribe To Our Newsletter & Stay Updated